Moderna Inc stock had added almost 6% on Wednesday morning after the biotechnology company reported positive results from a Phase 3 clinical study involving its vaccine targeting respiratory syncytial virus (RSV).
The company said its vaccine mRNA-1345 was 83.7% effective against at least two symptoms of RSV-associated lower respiratory tract disease in adults aged 60 years and older.
The vaccine was well-tolerated and no safety concerns were identified by an independent Data and Safety Monitoring Board, Moderna said.
READ: Moderna mulls Covid vaccine price hike as infections rise
“We look forward to publishing the full data set and sharing the results at an upcoming infectious disease medical conference,” commented Moderna CEO Stéphane Bancel.
Based on the results, Moderna intends to submit mRNA-1345 for regulatory approval in the first half of 2023.
RSV causes infections of the lungs and respiratory tract. According to the Centers for Disease Control and Prevention, it causes mild, cold-like symptoms in most people, but it can be serious in infants and older adults.
There is currently no approved vaccine for RSV.
Moderna stock had added 5.8% trading at US$201.75 at mid-morning on Wednesday.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie